Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to $105.4 million.

  • Foghorn Therapeutics' Cash from Financing Activities fell 95.34% to $49,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $446,000, marking a year-over-year decrease of 99.58%. This contributed to the annual value of $105.4 million for FY2024, which is 5829.58% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Cash from Financing Activities stood at $105.4 million for FY2024, which was up 5,829.58% from $1.8 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Cash from Financing Activities ranged from a high of $217.5 million in FY2020 and a low of $1.8 million during FY2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $1.8 million (2023), whereas its average is $36.3 million.
  • Per our database at Business Quant, Foghorn Therapeutics' Cash from Financing Activities slumped by 92.14% in 2022 and then surged by 5,829.58% in 2024.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Cash from Financing Activities stood at $217.5 million in 2020, then crashed by 89.69% to $22.4 million in 2021, then tumbled by 92.14% to $1.8 million in 2022, then rose by 0.85% to $1.8 million in 2023, then soared by 5,829.58% to $105.4 million in 2024.